DK3285756T3 - Formuleringer af l-ornithinphenylacetat - Google Patents

Formuleringer af l-ornithinphenylacetat Download PDF

Info

Publication number
DK3285756T3
DK3285756T3 DK16783692.3T DK16783692T DK3285756T3 DK 3285756 T3 DK3285756 T3 DK 3285756T3 DK 16783692 T DK16783692 T DK 16783692T DK 3285756 T3 DK3285756 T3 DK 3285756T3
Authority
DK
Denmark
Prior art keywords
formulations
phenyl acetate
ornithine phenyl
ornithine
acetate
Prior art date
Application number
DK16783692.3T
Other languages
English (en)
Inventor
Laurene Wang
Kenneth Ruettimann
Mark Coffin
James Bernstein
Gary Goodson
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Application granted granted Critical
Publication of DK3285756T3 publication Critical patent/DK3285756T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16783692.3T 2015-04-20 2016-04-19 Formuleringer af l-ornithinphenylacetat DK3285756T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562150238P 2015-04-20 2015-04-20
US201562150676P 2015-04-21 2015-04-21
US201562211619P 2015-08-28 2015-08-28
US201562255300P 2015-11-13 2015-11-13
US201662276754P 2016-01-08 2016-01-08
PCT/US2016/028298 WO2016172112A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate

Publications (1)

Publication Number Publication Date
DK3285756T3 true DK3285756T3 (da) 2023-05-08

Family

ID=57144228

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16783692.3T DK3285756T3 (da) 2015-04-20 2016-04-19 Formuleringer af l-ornithinphenylacetat

Country Status (13)

Country Link
US (2) US20160338982A1 (da)
EP (2) EP4205735A1 (da)
JP (2) JP2018513171A (da)
KR (1) KR20180006904A (da)
CN (2) CN107708684A (da)
AU (2) AU2016252382A1 (da)
CA (1) CA2983146C (da)
DK (1) DK3285756T3 (da)
ES (1) ES2944311T3 (da)
HK (1) HK1251149A1 (da)
MX (2) MX2017013170A (da)
RU (1) RU2755904C2 (da)
WO (1) WO2016172112A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
PL2413924T3 (pl) 2009-04-03 2018-02-28 Ocera Therapeutics, Inc. Fenylooctan l-ornityny i sposoby jego wytwarzania
KR20170026672A (ko) 2009-06-08 2017-03-08 유씨엘 비즈니스 피엘씨 L―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
CN113633777A (zh) 2014-11-24 2021-11-12 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
WO2017031131A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
KR20180086431A (ko) * 2015-11-13 2018-07-31 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제제
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CA3063134A1 (en) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Processes of making l-ornithine phenylacetate
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
SI2153870T1 (sl) * 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
PL2413924T3 (pl) 2009-04-03 2018-02-28 Ocera Therapeutics, Inc. Fenylooctan l-ornityny i sposoby jego wytwarzania
AU2015221466B2 (en) * 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
KR20170026672A (ko) * 2009-06-08 2017-03-08 유씨엘 비즈니스 피엘씨 L―오르니틴 페닐아세테이트를 사용한 문맥압 항진증의 치료 및 간 기능 회복
AU2014250643B2 (en) * 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
TR201903978T4 (tr) 2010-10-06 2019-04-22 Ocera Therapeutics Inc L-ornitin fenil asetat yapım yöntemleri.

Also Published As

Publication number Publication date
MX2017013170A (es) 2018-04-11
KR20180006904A (ko) 2018-01-19
CN113599350A (zh) 2021-11-05
RU2017137643A (ru) 2019-05-20
RU2755904C2 (ru) 2021-09-22
JP2022101549A (ja) 2022-07-06
AU2016252382A1 (en) 2017-11-02
US20220184014A1 (en) 2022-06-16
EP3285756A4 (en) 2019-01-23
MX2022003855A (es) 2023-03-02
CN107708684A (zh) 2018-02-16
AU2021200740A1 (en) 2021-03-04
WO2016172112A1 (en) 2016-10-27
CA2983146C (en) 2023-09-12
ES2944311T3 (es) 2023-06-20
RU2017137643A3 (da) 2019-09-17
JP2018513171A (ja) 2018-05-24
US20160338982A1 (en) 2016-11-24
HK1251149A1 (zh) 2019-01-25
EP3285756A1 (en) 2018-02-28
EP3285756B1 (en) 2023-02-22
CA2983146A1 (en) 2016-10-27
EP4205735A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
DK3285756T3 (da) Formuleringer af l-ornithinphenylacetat
DK3626081T3 (da) Pasteuriseret akkermansia til fremme af vægttab
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3292134T3 (da) Metode til dyrkning af akkermansia
DK3244891T3 (da) Forbindelser til forbedring af mrna-splejsning
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3180331T3 (da) Polymorfer af selinexor
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3334726T3 (da) Plinabulinsammensætninger
DK3250182T3 (da) Dispergible sammensætninger
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3220891T3 (da) Sublingual formulering af riluzol
MA42692A (fr) Compositions biopharmaceutiques
DK3307267T3 (da) Behandling af multipel sklerose
DK3261608T5 (da) Sammensætninger omfattende kombinationer af organiske syrer
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation